L-Allylglycine – 250 mg

Brand:
Cayman
CAS:
16338-48-0
Storage:
-20
UN-No:
Non-Hazardous - /

L-Allylglycine is an amino acid derivative that reduces glutamate decarboxylase (GAD) activity by 60% when administered at a dose of 39.8 μmol/g per hour ex vivo in mouse brain preparations.{36239} L-Allylglycine (1.2 mmol/kg, i.p.) induces convulsions and decreases GABA concentration throughout the cerebellum, pons, medulla, striatum, cortex, and hippocampus in mice.{36240} Chronic administration (3.2 μg/0.5 μl per hour for 13 days) of L-allylglycine in rats increases locomotor activity in an open field test and impairs attention in the 5-choice serial reaction time task (5CSRTT).{36241} In vitro, L-allylglycine inhibits GAD only when used at high concentrations (1-80 mM). The more potent in vivo activity can be attributed to metabolic conversion of L-allylglycine to 2-keto-4-pentanoic acid, a more potent convulsant and GAD inhibitor.  

 

Available on backorder

SKU: 23348 - 250 mg Category:

Description

A GAD inhibitor; reduces GAD activity by 60% when administered at a dose of 39.8 μmol/g per hour ex vivo in mouse brain preparations; i.p. administration (1.2 mmol/kg) induces convulsions and decreases GABA concentration throughout the cerebellum, pons, medulla, striatum, cortex, and hippocampus in mice; chronic administration (3.2 μg/0.5 μl per hour for 13 days) increases locomotor activity in an open field test and impairs attention in the 5-choice serial reaction time task (5CSRTT); inhibits GAD in vitro only when used at high concentrations (1-80 mM)


Formal name: 2S-amino-4-pentenoic acid

Synonyms: 

Molecular weight: 115.1

CAS: 16338-48-0

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Neuroscience|Seizure Disorders